TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03538080

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACCUVEIN plus ultrasound
Description: Intervention is marking of the saphenous veins with ACCUVEIN system. The AccuVein® AV400 vein illumination system is a laser imaging system that detects superficial veins up to 10 mm deep and digitally displays, through a projected red light, a map of the vascularization on the surface of the skin. in real time, allowing clinicians to check vein permeability and position.~This system is portable and lightweight. It can be easily cleaned, and requires no calibration or adjustment. It does not require any contact with the patient. Second time is completion of marking by ultrasound if necessary

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Ultrasound only
Description: Intervention is marking with ultrasound imaging as in usual practice.
Study: NCT02145455

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Unity Total Knee Replacement System

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Unity Total Knee Replacement System
Study: NCT02351947

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: upper limb rehabilitation for chronic stroke
Description: subjects in this group will receive upper limb motor learning rehabilitation and undergo fMRI/EEG testing as well as testing of motor function (AMAT and FM).
Study: NCT00887484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BENZOYL PEROXIDE/ CLINDAMYCIN
Description: Commencing at baseline, subjects will apply once daily both treatment arm #1 and treatment arm #2 in a bilateral split-face fashion (allocation to left and right side randomly assigned) for an initial 2 weeks. At 2 weeks, subjects will apply benzoyl peroxide/clindamycin gel to the entire face for an additional 6 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BENZOYL PEROXIDE/ ADAPALENE
Description: Commencing at baseline, subjects will apply once daily both treatment arm #1 and treatment arm #2 in a bilateral split-face fashion (allocation to left and right side randomly assigned) for an initial 2 weeks. At 2 weeks, subjects will apply benzoyl peroxide/clindamycin gel to the entire face for an additional 6 weeks.
Study: NCT01061606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temsirolimus
Description: Given IV
Study: NCT03664115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg
Description: itraconazole 200 mg oral tablet daily, on a 21-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: intravenous doses of cisplatin 80 mg/m2 on day 1 plus gemcitabine 1000 mg/m2 on days 1 and 8 every 3 weeks for a maximum of 6 cycles.~Alternatively, Carboplatin may be used instead of Cisplatin, Carbplatin AUC 5 DAY 1 only Dose = AUC x (GFR + 25) IV in 250 mL Normal Saline over 30 minutes
Study: NCT04018638

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: B-FREE
Description: Blood flow-restriction exercise enhancement (B-FREE) will be performed at home 3x/wk for 10 weeks. A blood pressure cuff will be inflated to partially occlude blood to the limb during light weight exercises involving knee extension, body weight squats, and walking.
Study: NCT03614949

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT)
Description: SBRT with 24 Gy in 3 fractions to participants with ≥ 2 metastatic sites.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 1200 mg intravenously (IV) every 3 weeks.
Study: NCT06727474

Intervention type: DIAGNOSTIC_TEST
Intervention: Health-Related Quality of Life (HRQoL) with EQ-5D-3L
Description: The EQ-5D-3L and EQ-VAS questionnaires, administered at all visits, evaluated five dimensions: mobility, self-care, daily activities, pain/discomfort, and anxiety/depression. Responses generated a Health Status sequence and calculated the EQ-5D-3L Index. A visual analogue scale (VAS) rated health from 0 (worst) to 100 (best). Functional capacity was assessed using the Katz Index (IK) and Timed Up and Go (TUG), which measured the time to rise from a chair, walk 3 meters, and return. Anthropometric variables, measured by the same researcher (LP) at 1 month and 1 year, included limb circumferences using specific techniques. Muscle strength, evaluated with the EF-MRC scale, involved verbal commands for movement tests. Calf circumference was measured on the largest circumference area. Living conditions and work reintegration were recorded. Health issues detected during follow-up were referred to the clinic's coordinating physician for appropriate care.
Study: NCT03345576

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Testosterone and LPWS
Description: Twelve patients will undergo 1 year of supervised training examining the effects of testosterone replacement therapy (TRT) and long pulse width stimulation (LPWS) in persons with denervated spinal cord injury.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Testosterone and standard NMES
Description: Twelve patients will undergo 1 year of supervised training examining the effects of testosterone replacement therapy (TRT) and standard surface neuromuscular electrical stimulation (NMES) in persons with denervated spinal cord injury.
Study: NCT03492125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MS-553
Description: Oral, multiple dose levels

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MS-553
Description: Oral, multiple dose levels

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MS-553
Description: Oral, multiple dose levels

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MS-553
Description: Oral recommended phase 2 dose of MS-553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MS-553
Description: Oral recommended phase 2 dose of MS-553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MS-553
Description: Oral recommended phase 2 dose of MS-553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MS-553
Description: Oral recommended phase 2 dose of MS-553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MS-553
Description: Oral recommended phase 2 dose of MS-553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acalabrutinib
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acalabrutinib
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acalabrutinib
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venetoclax
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venetoclax
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: obinutuzumab
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: obinutuzumab
Description: IV
Study: NCT03664115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: intravenous doses of cisplatin 80 mg/m2 on day 1 plus gemcitabine 1000 mg/m2 on days 1 and 8 every 3 weeks for a maximum of 6 cycles.~Alternatively, Carboplatin may be used instead of Cisplatin, Carbplatin AUC 5 DAY 1 only Dose = AUC x (GFR + 25) IV in 250 mL Normal Saline over 30 minutes
Study: NCT02371681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment
Description: Different Drug combinations

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET/CT Scan
Description: PET/CT Scans

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sample Collection
Description: Sample Collection
Study: NCT01204671

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine GSK2321138A
Description: One intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine GSK2321138A
Description: One intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine GSK2321138A
Description: One intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FluarixTM
Description: One intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza vaccine GSK2604409A
Description: One intramuscular injection
Study: NCT04185038

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCRI-CARB7H3(s); B7H3-specific chimeric antigen receptor (CAR) T cel
Description: Autologous CD4+ and CD8+ T cells lentivirally transduced to express a B7H3 specific chimeric antigen receptor (CAR) and EGFRt given via indwelling central nervous system (CNS) catheter

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCRI-CARB7H3(s); B7H3-specific chimeric antigen receptor (CAR) T cel
Description: Autologous CD4+ and CD8+ T cells lentivirally transduced to express a B7H3 specific chimeric antigen receptor (CAR) and EGFRt given via indwelling central nervous system (CNS) catheter

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCRI-CARB7H3(s); B7H3-specific chimeric antigen receptor (CAR) T cel
Description: Autologous CD4+ and CD8+ T cells lentivirally transduced to express a B7H3 specific chimeric antigen receptor (CAR) and EGFRt given via indwelling central nervous system (CNS) catheter
Study: NCT01012817

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT02573714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Intranasal ketamine (concentration: 50 mg/ml, dose: 1 mg/kg) will be given at time zero. Intranasal administration will be performed by placing the needleless syringe gently into the nares with the patient sitting upright. Volumes of ≤ 0.75ml will be nasally inhaled in a single nare, while volumes \> 0.75ml will be divided between both nares. Patients who are unable to inhale the medication nasally will receive drip administration of the same volume while recumbent on the bed.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Intranasal normal saline (placebo: volume-matched with intranasal ketamine) will be given at time zero. Intranasal administration will be performed by placing the needleless syringe gently into the nares with the patient sitting upright. Volumes of ≤ 0.75ml will be nasally inhaled in a single nare, while volumes \> 0.75ml will be divided between both nares. Patients who are unable to inhale the medication nasally will receive drip administration of the same volume while recumbent on the bed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Pain Therapy
Description: Typical management strategy for pediatric sickle cell disease vasoocclusive crises including acetaminophen/paracetamol, ibuprofen, oral opioids, and injectable opioids depending on pain severity.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard Pain Therapy
Description: Typical management strategy for pediatric sickle cell disease vasoocclusive crises including acetaminophen/paracetamol, ibuprofen, oral opioids, and injectable opioids depending on pain severity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pediatric Quality of Life - Sickle Cell Disease Module
Description: Standardized quality of life assessment performed 2-3 weeks post intranasal medication administration to evaluate pain management and severity of symptoms after discharge from the hospital.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Pediatric Quality of Life - Sickle Cell Disease Module
Description: Standardized quality of life assessment performed 2-3 weeks post intranasal medication administration to evaluate pain management and severity of symptoms after discharge from the hospital.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Faces Pain Scale - Revised
Description: All patients will answer the FPS-R at 0 minutes (immediately prior to receiving intranasal medication), 30 minutes, 60 minutes, and 120 minutes to assess current pain status.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Faces Pain Scale - Revised
Description: All patients will answer the FPS-R at 0 minutes (immediately prior to receiving intranasal medication), 30 minutes, 60 minutes, and 120 minutes to assess current pain status.
Study: NCT03181152

Intervention type: DIAGNOSTIC_TEST
Intervention: Impulse Oscillometry
Description: 1，Before the experiment, the patient is arranged to rest 10min. 2, IOS: The patient take seats, body relax, make sure the mouthpiece is fully covered by mouth, then clip nose with both hands to cover both sides of the cheek, and then calm breathing 1 minutes, the computer is automatically collected data calculation and print out the measurement results.~3, Bronchial Dilation Test: The patient is asked to take IOS again after gaven aerosol inhalation of 200g salbutamol for 15min, the computer is automatically collects the data computation and prints the measurement result.

Intervention type: DIAGNOSTIC_TEST
Intervention: Impulse Oscillometry
Description: 1，Before the experiment, the patient is arranged to rest 10min. 2, IOS: The patient take seats, body relax, make sure the mouthpiece is fully covered by mouth, then clip nose with both hands to cover both sides of the cheek, and then calm breathing 1 minutes, the computer is automatically collected data calculation and print out the measurement results.~3, Bronchial Dilation Test: The patient is asked to take IOS again after gaven aerosol inhalation of 200g salbutamol for 15min, the computer is automatically collects the data computation and prints the measurement result.

Intervention type: DIAGNOSTIC_TEST
Intervention: Impulse Oscillometry
Description: 1，Before the experiment, the patient is arranged to rest 10min. 2, IOS: The patient take seats, body relax, make sure the mouthpiece is fully covered by mouth, then clip nose with both hands to cover both sides of the cheek, and then calm breathing 1 minutes, the computer is automatically collected data calculation and print out the measurement results.~3, Bronchial Dilation Test: The patient is asked to take IOS again after gaven aerosol inhalation of 200g salbutamol for 15min, the computer is automatically collects the data computation and prints the measurement result.
Study: NCT01012817

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacogenomic Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Given PO
Study: NCT03625544

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Instrumented posterolateral spinal fusion
Description: Instrumented posterolateral spinal fusion, with or without an additional interbody device

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Instrumented posterolateral spinal fusion
Description: Instrumented posterolateral spinal fusion, with or without an additional interbody device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MagnetOs™ Granules
Description: 8-10cc of MagnetOs™ Granules per spinal level at the randomized allocation side of the spine (left or right)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autologous bone graft
Description: 8-10cc autologous bone graft per spinal level at the control side of the spine (left or right). This can be a combination of local bone and iliac crest bone, but at least 50% of the volume has to be iliac crest bone graft.
Study: NCT04393649

Intervention type: OTHER
Intervention: ESOGER
Description: Questionnaire
Study: NCT03861026

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bilateral NIRS (Masimo, O3TM Regional Oximetry)
Description: Bilateral NIRS (Masimo, O3TM Regional Oximetry) will be used to measure rSO2 intraoperatively. The NIRS electrodes will be placed on fronto-temporal area and baseline values of rSO2 obtained according to manufacturer's guidelines in the operating room prior to induction of anesthesia. The NIRS screen will be concealed in the control group to ensure blinding.
Study: NCT01035749

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' Influenza investigational vaccine GSK2340274A
Description: One or two doses administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' Influenza investigational vaccine GSK2340274A
Description: One or two doses administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' Influenza investigational vaccine GSK2340274A
Description: One or two doses administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' Influenza investigational vaccine GSK2340273A
Description: Two doses intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo (saline)
Description: One dose intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo (saline)
Description: One dose intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo (saline)
Description: One dose intramuscularly
Study: NCT01535924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bendamustine hydrochloride
Description: Given IV
Study: NCT04346953

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video based exercise
Description: Individuals (n = 64) to be included in the study group will be grouped according to the levels of physical activity (low, medium, high level) determined by the International Physical Activity Questionnaire. An exercise program will be created for each group based on physical activity levels and videos of these exercise programs will be prepared. The videos will be scheduled for 20 minutes. Individuals will be asked to apply for these programs with video for 20 minutes every day for 6 weeks. Exercise programs will start with pulmonary exercises and warm-up exercises to prepare for exercise. The exercise program will end with cool down exercises. The exercise protocol will be determined as a combination of aerobic and strengthening exercises.
Study: NCT03035162

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: Dual Active/sham tDCS will be applied over the leg motor area (M1) priori to conventional physical therapy (1 hours). Anodal on affected hemisphere, Cathodal on unaffected hemisphere. Each participant will complete two experiments (active/sham tDCS). The interval between two experiments is at least 48 hours. The two experiments will be performed in random order for each subject.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: Dual Active/sham tDCS will be applied over the leg motor area (M1) priori to conventional physical therapy (1 hours). Anodal on affected hemisphere, Cathodal on unaffected hemisphere. Each participant will complete two experiments (active/sham tDCS). The interval between two experiments is at least 48 hours. The two experiments will be performed in random order for each subject.
Study: NCT02783638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YHD1119
Description: 2 by 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lyrica
Description: 2 by 2
Study: NCT01100502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: Every 21 days by IV infusion (1.8 mg/kg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Every 21 days by IV infusion
Study: NCT00948090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Busulfan, Cyclophosphamide and Etoposide (BuCyE Regimen)
Description: Pk-directed IV Busulfan (based on test dose method) for 4 days followed by Etoposide 1400mg/m2 QD for one day and Cyclophosphamide 2.5 g/m2 QD for two days followed by autologous stem cell transplant.
Study: NCT01118052

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEG-PEI-cholesterol Lipopolymer-encased IL-12 DNA Plasmid Vector GEN-1
Description: Given intraperitoneally
Study: NCT00100906

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IL-2
Description: Immunotherapy with interleukin-2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IL-2
Description: Immunotherapy with interleukin-2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IL-2
Description: Immunotherapy with interleukin-2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATRA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATRA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATRA
Study: NCT00057135

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Unit of use medication packaging

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mailed reminders to patient when medication refills are due

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Note to Mental Health Provider when refill is overdue

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Aligning all prescriptions to fall due on same date
Study: NCT02001571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: On the morning of Day 1, each participant was given four 250 mg tablets of abiraterone acetate with 240 mL of room temperature tap water. Dosing followed at least a 10-hour fast from food (not including water).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: On the morning of Day 1, each participant was given four 250 mg tablets of abiraterone acetate with 240 mL of room temperature tap water. Dosing followed at least a 10-hour fast from food (not including water).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: On the morning of Day 1, each participant was given four 250 mg tablets of abiraterone acetate with 240 mL of room temperature tap water. Dosing followed at least a 10-hour fast from food (not including water).
Study: NCT02358122

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wholegrain rye
Description: A variety of cereal foods providing \>100g/day wholegrain from rye

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wholegrain wheat
Description: A variety of cereal foods providing \>100g/day wholegrain from wheat

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Refined wheat
Description: A variety of cereal foods providing 0g/day wholegrain
Study: NCT04000178

Intervention type: DEVICE
Group type: OTHER
Intervention: polyurethane stent
Description: patients were prospectively enrolled in the study and stratified (non-randomly) into either group A - polyurethane - control group or group B - silicone - experimental group

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: silicone stent
Description: silicone stent